Company Directory / Biotechnology

Public · NASDAQ:FOLDFor profitBiotechnologyPrinceton, NJ, United States
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his… Read all
We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his children were diagnosed with a rare disease. That spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies. Building on our core beliefs, our mission-focused behaviors help us define and shape our culture; drive performance and innovation; inform development and growth; and attract, energize, and retain the right talent. By championing mission-dedication, innovation, performance, and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. Our global footprint spans over 20 countries, including our global headquarters in Princeton, NJ and international headquarters in Marlow, UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain. More information about Amicus and our career opportunities can be found at www.amicusrx.com.
Size
501-1000 people: larger than 95% of companies with a size listed. 612 people list it on LinkedIn.
Age
24 years old.
Reach
Website ranked #2,757,644 in the world for traffic, about 6k visits a month. 48,329 followers on LinkedIn.
BiotechnologyHealth CarePharmaceuticalTherapeutics
Funding, as listed
$2.4B raised in total
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Everything the source datasets list about Amicus Therapeutics, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
Corporate family
About this record
Growth, as the source summarises it
Amicus Therapeutics opened a new global headquarters in Princeton. The company received the Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product. An analyst maintained a Buy rating on Amicus Therapeutics' stock amid competition.
Summaries written by the source dataset, not by us, and not checked.
Biotechnology in United States.
InsmedBridgewater Township · 501-1000 people · 51k followersSSAGE TherapeuticsCambridge · 501-1000 people · 111k followers
InvitaeSan Francisco · 1001-5000 people · 146k followers
GrailMenlo Park · 1001-5000 people
PacBioMenlo Park · 501-1000 people · 85k followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.